CN1292766C - 一种治疗病毒性心肌炎的中药制剂及其制备方法 - Google Patents
一种治疗病毒性心肌炎的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN1292766C CN1292766C CNB2003101239967A CN200310123996A CN1292766C CN 1292766 C CN1292766 C CN 1292766C CN B2003101239967 A CNB2003101239967 A CN B2003101239967A CN 200310123996 A CN200310123996 A CN 200310123996A CN 1292766 C CN1292766 C CN 1292766C
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- group
- treatment
- viral myocarditis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 60
- 206010047470 viral myocarditis Diseases 0.000 title claims description 40
- 238000000034 method Methods 0.000 title abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 235000014066 European mistletoe Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 244000152640 Rhipsalis cassutha Species 0.000 abstract 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 30
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 26
- 229930010555 Inosine Natural products 0.000 description 22
- 229960003786 inosine Drugs 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 208000009525 Myocarditis Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000003387 muscular Effects 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 4
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000001467 acupuncture Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000001047 pyretic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000713 mesentery Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- GZVMBXDQUQRICT-TZNWHQCUSA-N 3-[(3s,5r,8r,9s,10s,13r,14s)-14-hydroxy-3-[(2s,3r,4r,5r,6s)-3-hydroxy-4-methoxy-6-methyl-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6, Chemical compound C1([C@@]2(C)CC[C@H]3[C@H]([C@]2(CC1)O)CC[C@H]1[C@]3(C)CC[C@@H](C1)O[C@@H]1[C@H](O)[C@H]([C@@H]([C@H](C)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)OC)C1=CC(=O)OC1 GZVMBXDQUQRICT-TZNWHQCUSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930191001 Thevetin Natural products 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001092500 Photinia x fraseri Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 239000009912 gualou xiebai baijiutang Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 238000011430 maximum method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008945 zhigancao decoction Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 动物数(只) | 窦性心率 | 节律 | 心率(次/分) | 波形 | ||||
整齐 | 失常 | 正常 | 异常 | ||||||
ST段下移 | 频发房性早博 | QS | |||||||
空白对照组心肌炎模型对照组肌苷片治疗组本发明中药制剂治疗组(低)本发明中药制剂治疗组(中) | 1010101010 | 1010101010 | 100101010 | 010000 | 716±28509±42530±39658±26682±34 | 100101010 | 010000 | 010000 | 010000 |
本发明中药制剂治疗组(高) | 10 | 10 | 10 | 0 | 706±38 | 10 | 0 | 0 | 0 |
分组 | 动物(只) | 阳性 | 阴性 |
空白对照组心肌炎模型组肌苷片治疗组本发明中药制剂治疗组(低剂量)本发明中药制剂治疗组(中剂量)本发明中药制剂治疗组(高剂量) | 101010101010 | 0101100 | 100991010 |
组别 | 动物数(n) | 存活时间(min) | 与空白对照比较P值 |
空白对照组本发明中药制剂组(高)本发明中药制剂组(中)本发明中药制剂组(低) | 10101010 | 20.5±1.428.7±3.224.5±1.722.6±1.5 | ——<0.01<0.01<0.05 |
肌苷片组 | 10 | 21.7±1.3 | <0.05 |
组别 | 动物数(n) | 游泳时间(min) | 与空白对照比较P值 |
空白对照组本发明中药制剂组(高)本发明中药制剂组(中)本发明中药制剂组(低)肌苷片组 | 1010101010 | 37.5±8.968.4±14.154.2±16.244.1±10.348.3±12.1 | <0.01<0.01<0.05<0.05 |
组别 | 动物数 | 管径 | 流速 | 与空白对照比较P值 |
空白对照组本发明中药制剂组(高)本发明中药制剂组(中)本发明中药制剂组(低)肌苷片组 | 1010101010 | 3.40±0.178.51±0.146.51±0.124.12±0.187.84±0.13 | 4.32±0.299.12±0.247.32±0.205.12±0.318.42±0.30 | <0.01<0.01<0.05<0.01 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101239967A CN1292766C (zh) | 2002-12-31 | 2003-12-25 | 一种治疗病毒性心肌炎的中药制剂及其制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN02159094 | 2002-12-31 | ||
CN02159094.X | 2002-12-31 | ||
CNB2003101239967A CN1292766C (zh) | 2002-12-31 | 2003-12-25 | 一种治疗病毒性心肌炎的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1513542A CN1513542A (zh) | 2004-07-21 |
CN1292766C true CN1292766C (zh) | 2007-01-03 |
Family
ID=34276123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101239967A Expired - Fee Related CN1292766C (zh) | 2002-12-31 | 2003-12-25 | 一种治疗病毒性心肌炎的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1292766C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1327845C (zh) * | 2004-10-19 | 2007-07-25 | 哈尔滨医科大学 | 一种治疗心脑血管病的中药 |
CN101439082B (zh) * | 2007-11-22 | 2012-07-04 | 天津天士力制药股份有限公司 | 一种含苦参提取物的中药颗粒及其制备方法 |
CN102160884B (zh) * | 2010-02-24 | 2012-09-05 | 吕凌燕 | 治疗急性期病毒性心肌炎的中药制剂 |
CN104258082A (zh) * | 2014-10-21 | 2015-01-07 | 万爱玲 | 一种治疗心脾两虚型病毒性心肌炎的中药 |
CN105327197A (zh) * | 2015-12-16 | 2016-02-17 | 朱惠连 | 一种治疗湿热内侵型小儿病毒性心肌炎的中药 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1107714A (zh) * | 1994-03-04 | 1995-09-06 | 李永光 | 寸丹正心散 |
CN1311016A (zh) * | 2001-01-21 | 2001-09-05 | 程志清 | 一种治疗病毒性心肌炎的中药及其制剂工艺 |
-
2003
- 2003-12-25 CN CNB2003101239967A patent/CN1292766C/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1107714A (zh) * | 1994-03-04 | 1995-09-06 | 李永光 | 寸丹正心散 |
CN1311016A (zh) * | 2001-01-21 | 2001-09-05 | 程志清 | 一种治疗病毒性心肌炎的中药及其制剂工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN1513542A (zh) | 2004-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101703708B (zh) | 一种治疗类风湿关节炎、痛风的中药制剂及其制备方法 | |
CN101390994B (zh) | 一种治疗带状疱疹的药物 | |
CN1742939A (zh) | 一种治疗肺间质纤维化的药物及其制备方法 | |
CN1390585A (zh) | 神阙排毒中药组合物及其制备方法 | |
CN1292766C (zh) | 一种治疗病毒性心肌炎的中药制剂及其制备方法 | |
CN102847061B (zh) | 一种治疗小儿病毒性心肌炎的中药制剂及其制备方法 | |
CN101199749A (zh) | 一种治疗艾滋病的中药 | |
CN1440804A (zh) | 一种降血脂的中药 | |
CN1686210A (zh) | 一种治疗乙型肝炎的中药制剂 | |
CN1290545C (zh) | 一种治疗冠心病的中药制剂及其制备方法和应用 | |
CN1319587C (zh) | 肝脾灵粉 | |
CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
CN1169555C (zh) | 一种治疗乙型肝炎实证的乙肝化毒煎丸剂 | |
CN1907345A (zh) | 一种治疗脑中风的中药组合物 | |
CN1190229C (zh) | 一种治疗乙型肝炎的药物 | |
CN1173718C (zh) | 一种治疗红斑狼疮免疫疾病所致痹症的药物 | |
CN1117576C (zh) | 一种调节肝脾功能的中成药 | |
CN1126558C (zh) | 一种治疗红斑狼疮所致肾脏损害的药物 | |
CN112206279B (zh) | 一种治疗室性心律失常的中药组合物及其制备方法和应用 | |
CN1309412C (zh) | 一种治疗艾滋病的药物组合物及其制备方法 | |
CN1212150C (zh) | 治疗病毒性肝炎的药物及制备方法 | |
CN1064544C (zh) | 一种治疗肝病的中药肝愈散 | |
CN1352966A (zh) | 治疗气管炎、哮喘病的药物 | |
CN1269517C (zh) | 抗艾滋病毒口服液 | |
CN1611258A (zh) | 一种治疗伤寒的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070103 Termination date: 20191225 |
|
CF01 | Termination of patent right due to non-payment of annual fee |